HOME >> BIOLOGY >> NEWS
Personalized approach to ovarian stimulation achieves high ART pregnancy rates

Lyon, France -- An international group of fertility specialists has developed an easy-to use mathematical formula that allows a personalised approach to ovarian stimulation therapy for women seeking fertility treatment. Clinical tests demonstrated that when clinicians used the formula (or algorithm) to calculate the best starting dose for each patient, both the number of oocytes retrieved and pregnancy rates rose.

Professor Franois Olivennes told the 23rd annual meeting of the European Society of Human Reproduction and Embryology today (Monday 2 July) that the algorithm was based on four factors that predicted ovarian response and that were measured routinely when women were evaluated for fertility treatment: normal (or basal) levels of follicle stimulating hormone (FSH), body mass index, age and the number of small growing (antral) follicles in the ovary detected during screening.

This FSH dose algorithm is simple and easy to use and utilises readily available patient characteristics, said Prof Olivennes, coordinator of the Centre de FIV Eylau La Muette, Paris, France. It is the first to be tested in a prospective multi-national clinical study and it provided each patient with an individualised starting dose of FSH, which could be maintained throughout treatment and resulted in an excellent treatment outcome as testified by the number of oocytes retrieved and the high pregnancy rates.

This approach should enable us to improve patient management, treatment outcomes and safety by reducing the chances of having to either cancel cycles because the ovaries have not been stimulated enough or of ovarian hyperstimulation syndrome (OHSS) developing because the ovaries have been over-stimulated.

Moderate or severe OHSS can occur in 3-8% of IVF cycles [1]. Moderate OHSS can be accompanied by nausea and vomiting. Severe OHSS, which is an uncommon event, can be accompanied by ovarian enlargement and fluid imbalances, sometimes resulti
'"/>

Contact: Emma Mason
wordmason@mac.com
European Society for Human Reproduction and Embryology
2-Jul-2007


Page: 1 2 3

Related biology news :

1. Personalized medicine, future of pharmaceuticals explored in UH lecture
2. Personalized treatments according to type of obesity
3. Researchers use new approach to predict protein function
4. New approach to pulmonary hypertension shows promise
5. New approaches to endometriosis treatment -- mouse experiments point the way
6. Reconstructing the biology of extinct species: A new approach
7. Screening approach leads to discovery of gene linked to breast cancer
8. In new statistical approach, data decide model
9. Bigelow Laboratory Scientists develop new approach to study marine microbes
10. New understanding of schizophrenia could lead to new treatment approaches
11. Cheaper, better disease treatments expected from faster approach to developing antibodies

Post Your Comments:
(Date:4/17/2014)... Mo. April 17 In the most densely forested ... forests reflect two centuries of human needs, values and ... and clearing forests for agriculture and development, have set ... a U.S. Forest Service study reports. , The report ... conditions and management needs in the Northern United States ...
(Date:4/17/2014)... Rochelle, NY, April 17, 2014The development of stem cell ... the ability to characterize stem cell populations based on ... have discovered a new marker that is highly expressed ... umbilical cord blood, which they describe in an article ... from Mary Ann Liebert, Inc., publishers. The article is ...
(Date:4/17/2014)... ALBUQUERQUE, N.M. A credit-card-sized anthrax detection cartridge developed ... small business makes testing safer, easier, faster and cheaper. ... causes anthrax, is commonly found in soils all over ... illness in both humans and animals. The bacteria can ... to B. anthracis may occur through skin ...
Breaking Biology News(10 mins):Five anthropogenic factors that will radically alter northern forests in 50 years 2Five anthropogenic factors that will radically alter northern forests in 50 years 3Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3
(Date:1/15/2014)... 2014 The Pittcon Organizing Committee is pleased ... Safety Tech , an e-Journal and producer of ... the second year for the co-location of Food Labs Conference ... provides that the registration fee to attend the two-day Food ...
(Date:1/15/2014)... Jan. 15, 2014 ­ RedBrick Health , a ... technology, today announces that EmblemHealth , the ... company, is now providing the RedBrick Compass health assessment, ... to all of its members. EmblemHealth is among the ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent viruses ... is the Epstein Barr Virus (EBV), and one of these ... chronic inflammatory disease that destroys the body’s joints. As predicted ... high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today announced ... a leading Russian pharmaceutical company, to develop and commercialize ... Federation , Turkey and ... a novel antibiotic for the treatment of bacterial infections ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
Cached News: